Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Eledon Pharmaceuticals Inc ELDN

Healthcare Biotechnology
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L... see more

Recent & Breaking News (NDAQ:ELDN)

Eledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation

GlobeNewswire August 16, 2023

Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results

GlobeNewswire August 10, 2023

Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference

GlobeNewswire June 2, 2023

Eledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Results

GlobeNewswire May 11, 2023

Eledon Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

GlobeNewswire May 4, 2023

Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials

GlobeNewswire May 1, 2023

Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology

GlobeNewswire March 31, 2023

Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results

GlobeNewswire March 30, 2023

Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023

GlobeNewswire March 23, 2023

Eledon to Present Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation at the World Congress of Nephrology 2023

GlobeNewswire March 23, 2023

Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference

GlobeNewswire February 8, 2023

Eledon Pharmaceuticals Provides Business and Pipeline Updates

GlobeNewswire January 9, 2023

C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System

GlobeNewswire December 21, 2022

Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results

GlobeNewswire November 14, 2022

Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

GlobeNewswire November 3, 2022

Eledon Pharmaceuticals Announces Upcoming Presentations at ASN's Kidney Week 2022 and NEALS

GlobeNewswire October 24, 2022

Eledon Pharmaceuticals to Participate in Two Upcoming Conferences

GlobeNewswire October 3, 2022

Eledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference

GlobeNewswire September 22, 2022

Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy

GlobeNewswire September 6, 2022

Eledon Pharmaceuticals to Participate in Two Upcoming Investor Conferences

GlobeNewswire August 29, 2022